Regulatory Compliance for Enterprise AI

Executive Summary

Enterprise AI deployments in regulated industries must navigate a complex and rapidly evolving compliance landscape: HIPAA for healthcare data, SOC 2 Type II for operational security assurance, HITRUST CSF for healthcare-specific security certification, FDA regulations for AI as a medical device, and the EU AI Act for systems deployed in the European Union. Each framework makes distinct demands on how AI systems are designed, operated, documented, and audited. This chapter maps each framework to the specific AI implementation requirements it creates, with emphasis on the clinical AI context.

Learning Objectives

  • Identify which regulatory frameworks apply to a specific clinical AI deployment
  • Map SOC 2 trust service criteria to AI platform control requirements
  • Understand FDA Software as a Medical Device (SaMD) classification for clinical AI
  • Apply EU AI Act high-risk AI system requirements to clinical decision support deployments

Enterprise Considerations

Regulatory overlap: HIPAA, SOC 2, HITRUST, and EU AI Act requirements frequently overlap. Map each requirement to a single implementation control rather than building separate compliance stacks. HITRUST CSF is specifically designed to harmonize HIPAA with other frameworks — use it as the single control framework if the organization is pursuing HITRUST certification.

Compliance as architecture: Regulatory requirements must be designed into the AI architecture from the beginning — not retrofitted. An AI system deployed without HIPAA audit logging cannot satisfy the HIPAA audit controls standard by adding logging after the fact to the same system that has already been used with PHI.

Evolving landscape: EU AI Act was published in 2024 with phased implementation timelines. FDA PCCP guidance evolves as clinical AI capabilities mature. HIPAA guidance on AI is developing. Establish a regulatory monitoring process to track changes that affect the AI platform.

Common Mistakes

1. Assuming SOC 2 covers HIPAA. SOC 2 is a security framework; HIPAA is a privacy and security law. An organization can be SOC 2 Type II certified while being out of HIPAA compliance. Both must be addressed independently.

2. Not classifying clinical AI as potentially SaMD. Organizations deploy clinical decision support AI without asking whether it meets FDA's definition of a medical device. If the AI is "intended to diagnose, treat, mitigate, cure, or prevent disease," it may require FDA clearance regardless of whether the organization considers it a "software tool."

3. Not including AI in the SOC 2 scope. SOC 2 audits cover the systems in scope. If the AI platform is not explicitly in scope, the audit does not cover AI controls. Ensure AI platform components are explicitly included in the SOC 2 scope definition.

Key Takeaways

  • Clinical AI is subject to multiple simultaneous regulatory frameworks: HIPAA (data privacy), SOC 2 (security assurance), HITRUST (healthcare security certification), FDA SaMD (medical device regulation), and EU AI Act (high-risk AI)
  • Each framework makes distinct implementation demands; map all to a single control implementation where possible
  • Clinical decision support AI is classified as high-risk under the EU AI Act, requiring conformity assessment and human oversight mechanisms
  • FDA SaMD classification must be evaluated before deploying AI for clinical decision support — "software tool" framing does not exempt clinical AI from medical device regulation
  • Compliance must be designed in from the start; it cannot be retrofitted to a deployed AI system

Further Reading